PRMT3 and rectal cancer: Acipimox, a clinically established hypolipidemic agent for non‐responsive patients,[51] exerts its action through lipolysis inhibition and free fatty acid flux reduction, impacting hepatic very‐low‐density lipoprotein (VLDL) synthesis and plasma lipid profiles.[52] Here, we found that acipimox improved therapeutic efficacy by inhibiting PRMT3 in rectal cancer.